Targeting NF-kB in glioblastoma: A therapeutic approach

Science Advances

Volumn 2, Issue 1, 2016, Pages

  Friedmann Morvinski, Dinorah ^a,b   Narasimamurthy, Rajesh ^a,c   Xia, Yifeng ^a   Myskiw, Chad ^a   Soda, Yasushi ^a   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; CELL CULTURE; GENE THERAPY; GENES; MAMMALS;

BINDING DOMAIN; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS; INTRACRANIAL TUMORS; MOLECULAR SIGNATURES; NUCLEAR FACTOR-KB; PATHOPHYSIOLOGY; TUMOR PROLIFERATION;

TUMORS;

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE;

ANIMAL; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; I-KAPPA B KINASE; MICE; MICE, INBRED NOD; MICE, SCID; NF-KAPPA B; PEPTIDES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84987654802     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1501292     Document Type: Article

References (36)

1. F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, L. Chin, R. A. DePinho, W. K. Cavenee, Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007).
2. J. T. Huse, E. C. Holland, Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319-331 (2010).
3. C. D. Stiles, D. H. Rowitch, Glioma stem cells: A midterm exam. Neuron 58, 832-846 (2008).
4. L. A. D. Cooper, J. Kong, D. A. Gutman, F. Wang, S. R. Cholleti, T. C. Pan, P. M. Widener, A. Sharma, T. Mikkelsen, A. E. Flanders, D. L. Rubin, E. G. Van Meir, T. M. Kurc, C. S. Moreno, D. J. Brat, J. H. Saltz, An integrative approach for in silico glioma research. IEEE Trans. Biomed. Eng. 57, 2617-2621 (2010).
5. J. T. Huse, H. S. Phillips, C. W. Brennan, Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia 59, 1190-1199 (2011).
6. H. S. Phillips, S. Kharbanda, R. Chen, W. F. Forrest, R. H. Soriano, T. D. Wu, A. Misra, J. M. Nigro, H. Colman, L. Soroceanu, P. M. Williams, Z. Modrusan, B. G. Feuerstein, K. Aldape, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
7. R. G. W. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, C. R. Miller, L. Ding, T. Golub, J. P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly, P. Tamayo, B. A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H. S. Feiler, J. G. Hodgson, C. D. James, J. N. Sarkaria, C. Brennan, A. Kahn, P. T. Spellman, R. K. Wilson, T. P. Speed, J. W. Gray, M. Meyerson, G. Getz, C. M. Perou, D. N. Hayes, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
8. K. P. L. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink, F. Hollingsworth, K. Wani, L. Heathcock, J. D. James, L. D. Goodman, S. Conroy, L. Long, N. Lelic, S. Wang, J. Gumin, D. Raj, Y. Kodama, A. Raghunathan, A. Olar, K. Joshi, C. E. Pelloski, A. Heimberger, S. H. Kim, D. P. Cahill, G. Rao, W. F. A. Den Dunnen, H. W. G. M. Boddeke, H. S. Phillips, I. Nakano, F. F. Lang, H. Colman, E. P. Sulman, K. Aldape, Mesenchymal differentiation mediated by NF-kB promotes radiation resistance in glioblastoma. Cancer Cell 24, 331-346 (2013).
9. Y. Xia, S. Shen, I. M. Verma, NF-kB, an active player in human cancers. Cancer Immunol. Res. 2, 823-830 (2014).
10. P. A. Robe, M. Bentires-Alj, M. Bonif, B. Rogister, M. Deprez, H. Haddada, M.-T. N. Khac, O. Jolois, K. Erkmen, M.-P. Merville, P. M. Black, V. Bours, In vitro and in vivo activity of the nuclear factor-kB inhibitor sulfasalazine in human glioblastomas. Clin. Cancer Res. 10, 5595-5603 (2004).
11. J. S. Gill, X. Zhu, M. J. Moore, L. Lu, M. J. Yaszemski, A. J. Windebank, Effects of NFkB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 23, 2773-2781 (2002).
12. D. W. Lee, D. Ramakrishnan, J. Valenta, I. F. Parney, K. J. Bayless, R. Sitcheran, The NF-kB RelB protein is an oncogenic driver of mesenchymal glioma. PLOS One 8, e57489 (2013).
13. S. Acharyya, S. A. Villalta, N. Bakkar, T. Bupha-Intr, P. M. L. Janssen, M. Carathers, Z.-W. Li, A. A. Beg, S. Ghosh, Z. Sahenk, M. Weinstein, K. L. Gardner, J. A. Rafael-Fortney, M. Karin, J. G. Tidball, A. S. Baldwin, D. C. Guttridge, Interplay of IKK/NF-kB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117, 889-901 (2007).
14. A. Ghosh, A. Roy, X. Liu, J. H. Kordower, E. J. Mufson, D. M. Hartley, S. Ghosh, R. L. Mosley, H. E. Gendelman, K. Pahan, Selective inhibition of NF-kB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 104, 18754-18759 (2007).
15. M. J. May, F. D'Acquisto, L. A. Madge, J. Glöckner, J. S. Pober, S. Ghosh, Selective inhibition of NF-kB activation by a peptide that blocks the interaction of NEMO with the IkB kinase complex. Science 289, 1550-1554 (2000).
16. G. Riddick, H. A. Fine, Integration and analysis of genome-scale data from gliomas. Nat. Rev. Neurol. 7, 439-450 (2011).
17. D. Friedmann-Morvinski, E. A. Bushong, E. Ke, Y. Soda, T. Marumoto, O. Singer, M. H. Ellisman, I. M. Verma, Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080-1084 (2012).
18. M. S. Carro, W. K. Lim, M. J. Alvarez, R. J. Bollo, X. Zhao, E. Y. Snyder, E. P. Sulman, S. L. Anne, F. Doetsch, H. Colman, A. Lasorella, K. Aldape, A. Califano, A. Iavarone, The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010).
19. T. Marumoto, A. Tashiro, D. Friedmann-Morvinski, M. Scadeng, Y. Soda, F. H. Gage, I. M. Verma, Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15, 110-116 (2009).
20. G. Habineza Ndikuyeze, A. Gaurnier-Hausser, R. Patel, A. S. Baldwin, M. J. May, P. Flood, E. Krick, K. J. Propert, N. J. Mason, A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. PLOS One 9, e95404 (2014).
21. J. S. Tilstra, D. F. Gaddy, J. Zhao, S. H. Davé, L. J. Niedernhofer, S. E. Plevy, P. D. Robbins, Pharmacologic IKK/NF-kB inhibition causes antigen presenting cells to undergo TNFa dependent ROS-mediated programmed cell death. Sci. Rep. 4, 3631 (2014).
22. W. Shibata, S. Maeda, Y. Hikiba, A. Yanai, T. Ohmae, K. Sakamoto, H. Nakagawa, K. Ogura, M. Omata, Cutting edge: The IkB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 179, 2681-2685 (2007).
23. M. S. Hayden, S. Ghosh, Signaling to NF-kB. Genes. Dev. 18, 2195-2224 (2004).
24. V. Bottero, S. Withoff, I. M. Verma, NF-kB and the regulation of hematopoiesis. Cell Death Differ. 13, 785-797 (2006).
25. Y. Xia, N. Yeddula, M. Leblanc, E. Ke, Y. Zhang, E. Oldfield, R. J. Shaw, I. M. Verma, Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 14, 257-265 (2012).
26. P. A. Robe, D. H. Martin, M. T. Nguyen-Khac, M. Artesi, M. Deprez, A. Albert, S. Vanbelle, S. Califice, M. Bredel, V. Bours, Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9, 372 (2009).
27. V. T. Puliyappadamba, K. J. Hatanpaa, S. Chakraborty, A. A. Habib, The role of NF-kB in the pathogenesis of glioma. Mol. Cell. Oncol. 1, e963478 (2014).
28. S. Bao, Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, M. W. Dewhirst, D. D. Bigner, J. N. Rich, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
29. T. M. Phillips, W. H. McBride, F. Pajonk, The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98, 1777-1785 (2006).
30. W. A. Woodward, M. S. Chen, F. Behbod, M. P. Alfaro, T. A. Buchholz, J. M. Rosen, WNT/bcatenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 104, 618-623 (2007).
31. P. di Meglio, A. Ianaro, S. Ghosh, Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kB activation. Arthritis Rheum. 52, 951-958 (2005).
32. L. Agemy, D. Friedmann-Morvinski, V. R. Kotamraju, L. Roth, K. N. Sugahara, O. M. Girard, R. F. Mattrey, I. M. Verma, E. Ruoslahti, Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 108, 17450-17455 (2011).
33. D. Friedmann-Morvinski, V. Bhargava, S. Gupta, I. M. Verma, S. Subramaniam, Identification of therapeutic targets for glioblastoma by network analysis. Oncogene 10.1038/onc.2015.119 (2015).
34. R. S. Samant, D. W. Clark, R. A. Fillmore, M. Cicek, B. J. Metge, K. H. Chandramouli, A. F. Chambers,G. Casey, D. R.Welch, L. A. Shevde, Breast cancermetastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kB activation. Mol. Cancer 6, 6 (2007).
35. M. Pasparakis, G. Courtois, M. Hafner, M. Schmidt-Supprian, A. Nenci, A. Toksoy, M. Krampert, M. Goebeler, R. Gillitzer, A. Israel, T. Krieg, K. Rajewsky, I. Haase, TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417, 861-866 (2002).
36. M. Ikawa, N. Tanaka, W. W.-Y. Kao, I. M. Verma, Generation of transgenic mice using lentiviral vectors: A novel preclinical assessment of lentiviral vectors for gene therapy. Mol. Ther. 8, 666-673 (2003).